Specialty
Novartis is a pioneer in the field of retinal disease and continues to be dedicated to the research, development and manufacturing of ophthalmic pharmaceuticals. Since 2000 we offer treatments for ocular conditions including “wet” age-related macular degeneration (AMD), a leading cause of blindness in people above the age of 50 years. Since 2011, Novartis also provides a treatment for visual impairment due to diabetic macular edema (DME) and for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO).
Our ophthalmics products include:
- Lucentis (ranibizumab)
- Visudyne (verteporfin)
